Literature DB >> 20454638

Communication: Antimicrobial Activity of SMAP28 with a Targeting Domain for Porphyromonas gingivalis.

Carol L Bratt1, Karl G Kohlgraf, Katie Yohnke, Colleen Kummet, Deborah V Dawson, Kim A Brogden.   

Abstract

Antibiotic therapy is often used with mechanical therapy to treat periodontal disease. However, complications associated with antibiotic use can occur. A 'bacteria-specific' targeted approach would eliminate some of these complications and kill specific periodontopathogens without harming the commensal bacteria. One such approach is to couple antimicrobial peptides to a ligand, pheromone, or antibody specific for the periodontopathogen, Porphyromonas gingivalis. To assess the feasibility of this approach, we attached PQGPPQ, a peptide from proline-rich protein 1 to either the N-terminus of SMAP28 (peptide ZS37-37) or the C-terminus of SMAP28 (peptide ZS37-38) to see whether it has potential as a carrier ligand to deliver SMAP28 to the surface of P. gingivalis. For Escherichia coli and Aggregatibacter actinomycetemcomitans, the median minimal inhibitory concentration (MIC) of ZS37-37 was higher than the median of SMAP28 alone, although the median MIC of ZS37-38 was lower than that of SMAP28 alone. For P. gingivalis, there was no difference in the median MIC values. For S. aureus, the median MIC was higher for ZS37-37 and ZS37-38 compared to SMAP28 alone, particularly for ZS37-38. For Fusobacterium nucleatum, the median MIC values were equal for ZS37-37 and ZS37-38 and higher than the median MIC for SMAP28 alone. Attaching PQGPPQ to SMAP28 did not greatly increase the antimicrobial activity of ZS37-37 or ZS37-38 for P. gingivalis nor substantially decrease the antimicrobial activity of ZS37-37 or ZS37-38 for the four other microorganisms tested. This is an initial step to develop a selective antimicrobial agent that has 'targeted' antimicrobial activity without adverse reactions often associated with the use of broad-spectrum antibiotics.

Entities:  

Year:  2010        PMID: 20454638      PMCID: PMC2863077          DOI: 10.1007/s12602-009-9028-5

Source DB:  PubMed          Journal:  Probiotics Antimicrob Proteins        ISSN: 1867-1306            Impact factor:   4.609


  11 in total

1.  Congeners of SMAP29 kill ovine pathogens and induce ultrastructural damage in bacterial cells.

Authors:  V C Kalfa; H P Jia; R A Kunkle; P B McCray; B F Tack; K A Brogden
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

2.  APD: the Antimicrobial Peptide Database.

Authors:  Zhe Wang; Guangshun Wang
Journal:  Nucleic Acids Res       Date:  2004-01-01       Impact factor: 16.971

3.  A novel engineered peptide, a narrow-spectrum antibiotic, is effective against vancomycin-resistant Enterococcus faecalis.

Authors:  Xiao-Qing Qiu; Jie Zhang; He Wang; George Y Wu
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Active sites of salivary proline-rich protein for binding to Porphyromonas gingivalis fimbriae.

Authors:  K Kataoka; A Amano; M Kuboniwa; H Horie; H Nagata; S Shizukuishi
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

5.  Secretion of functional salivary peptide by Streptococcus gordonii which inhibits fimbria-mediated adhesion of Porphyromonas gingivalis.

Authors:  K Kataoka; A Amano; S Kawabata; H Nagata; S Hamada; S Shizukuishi
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

6.  SMAP-29: a potent antibacterial and antifungal peptide from sheep leukocytes.

Authors:  B Skerlavaj; M Benincasa; A Risso; M Zanetti; R Gennaro
Journal:  FEBS Lett       Date:  1999-12-10       Impact factor: 4.124

Review 7.  Adverse reactions to antibiotics. Clues for recognizing, understanding, and avoiding them.

Authors:  R A Gleckman; F Borrego
Journal:  Postgrad Med       Date:  1997-04       Impact factor: 3.840

8.  Targeted antimicrobial activity of a specific IgG-SMAP28 conjugate against Porphyromonas gingivalis in a mixed culture.

Authors:  Michael R Franzman; Kindra K Burnell; Farideh H Dehkordi-Vakil; Janet M Guthmiller; Deborah V Dawson; Kim A Brogden
Journal:  Int J Antimicrob Agents       Date:  2008-09-07       Impact factor: 5.283

9.  An engineered multidomain bactericidal peptide as a model for targeted antibiotics against specific bacteria.

Authors:  Xiao-Qing Qiu; He Wang; Xiao-Fong Lu; Jie Zhang; Sheng-Fu Li; Gang Cheng; Lin Wan; Li Yang; Jun-Yong Zuo; Yu-Qi Zhou; Hai-Yun Wang; Xin Cheng; Su-Hua Zhang; Zheng-Rong Ou; Zi-Cheng Zhong; Jing-Qiu Cheng; You-Ping Li; George Y Wu
Journal:  Nat Biotechnol       Date:  2003-11-16       Impact factor: 54.908

10.  APD2: the updated antimicrobial peptide database and its application in peptide design.

Authors:  Guangshun Wang; Xia Li; Zhe Wang
Journal:  Nucleic Acids Res       Date:  2008-10-28       Impact factor: 16.971

View more
  3 in total

Review 1.  Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals?

Authors:  Nicole K Brogden; Kim A Brogden
Journal:  Int J Antimicrob Agents       Date:  2011-07-05       Impact factor: 5.283

Review 2.  Targeted antimicrobial therapy in the microbiome era.

Authors:  V N Stone; P Xu
Journal:  Mol Oral Microbiol       Date:  2017-08-01       Impact factor: 3.563

3.  Oral mucosal lipids are antibacterial against Porphyromonas gingivalis, induce ultrastructural damage, and alter bacterial lipid and protein compositions.

Authors:  Carol L Fischer; Katherine S Walters; David R Drake; Deborah V Dawson; Derek R Blanchette; Kim A Brogden; Philip W Wertz
Journal:  Int J Oral Sci       Date:  2013-07-19       Impact factor: 6.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.